Hans Lee, MD
Cardiovascular Disease · Marietta, GANPI 1881690857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 271 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Merck$483
- Pfizer$458
- Boston Scientific$409
- Abbott$400
- E.r. Squibb & Sons, L.L.C.$377
- plus $3K from 28 others
Across 42 payments — averaging $1864.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$46K
- Cvrx, Inc.$32K
- Regeneron$135
- Amgen$5
What the payments were for
- Food & beverage$6,491100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 56 | $1,010 |
| Merck | 27 | $483 |
| Pfizer | 26 | $458 |
| Boston Scientific | 13 | $409 |
| Abbott | 6 | $400 |
| E.r. Squibb & Sons, L.L.C. | 19 | $377 |
| Boehringer Ingelheim | 21 | $370 |
| Medtronic(2 entities) | 3 | $350 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $305 |
| Johnson & Johnson | 19 | $289 |
| Amgen | 12 | $230 |
| Bayer | 11 | $205 |
| Impulse Dynamics (USA) Inc. | 2 | $202 |
| Novo Nordisk | 8 | $168 |
| Penumbra, Inc. | 1 | $161 |
| ZOLL Respicardia, Inc. | 1 | $158 |
| Procyrion, Inc. | 1 | $136 |
| W. L. Gore & Associates, Inc. | 6 | $136 |
| Cvrx, Inc. | 1 | $83 |
| Lexicon Pharmaceuticals, Inc. | 4 | $77 |
| AstraZeneca | 4 | $74 |
| Amarin Pharma, Inc. | 4 | $66 |
| BD | 1 | $65 |
| Heartflow, Inc. | 2 | $58 |
| GSK | 2 | $38 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| United Therapeutics Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$356
- SYMPLICITY G3$163
- Indigo System$161
- remede System$158
- AORTIX SYSTEM$136
- MitraClip$133
- CardioMEMS HF System$117
- HeartWare HVAD$112
How this compares
$6,511 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $609,239 |
| EntrestoSacubitril/Valsartan | 206 | $247,197 |
| JardianceEmpagliflozin | 184 | $213,036 |
| CamzyosMavacamten | 23 | $188,444 |
| XareltoRivaroxaban | 117 | $110,794 |
| Repatha SureclickEvolocumab | 97 | $106,613 |
| FarxigaDapagliflozin Propanediol | 99 | $94,474 |
| MultaqDronedarone Hcl | 13 | $12,036 |
| BrilintaTicagrelor | 16 | $11,263 |
| Praluent PenAlirocumab | 16 | $11,103 |
| Ranolazine ErRanolazine | 55 | $8,784 |
| Ezetimibe | 366 | $8,656 |
| Potassium Chloride | 182 | $7,464 |
| Metoprolol Succinate | 532 | $7,004 |
| Rosuvastatin Calcium | 568 | $6,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $458 | $609,239537 claims |
| NovartisEntresto | $1,010 | $247,197206 claims |
| Boehringer IngelheimJardiance | $370 | $213,036184 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $377 | $188,44423 claims |
| Johnson & JohnsonXarelto | $289 | $110,794117 claims |
| AstraZenecaFarxiga, Brilinta | $74 | $105,736115 claims |
| Sanofi-aventis U.S. LLCMultaq | $26 | $12,03613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Marietta
- Dhaval PatelMarietta$67K
- George KramerMarietta$55K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.